# Lineage Cell Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2021

- Company: [Lineage Cell Therapeutics, Inc.](/companies/lctx.md) (CIK 876343)
- Form: 10-Q
- Filed: 2021-11-10
- Accepted by EDGAR: Nov 10, 2021, 16:16 ET
- Period: 2021-09-30
- Accession: 0001493152-21-027859
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/876343/000149315221027859/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/876343/000149315221027859/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $2.3m | us-gaap:Revenues |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $3.2m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2021-07-01 to 2021-09-30 | $985.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2021-01-01 to 2021-09-30 | $1.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2021-07-01 to 2021-09-30 | $1.3m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2021-01-01 to 2021-09-30 | $2.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-07-01 to 2021-09-30 | $2.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2021-01-01 to 2021-09-30 | $9.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | −$6.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | −$21.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | −$7.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | −$14.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | −$0.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | −$0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 167,624,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 163,120,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | −$17.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2021-09-30 | $60.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $68.3m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $131.2m | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $8.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $11.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-09-30 | $120.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/876343/000149315221027859/form10-q.htm

Filed Nov 10, 2021.
Source: SEC EDGAR, the filing index for accession 0001493152-21-027859. Last ingested by Listed: Nov 13, 2026, 16:09 ET. No prices; not investment advice.
